Mystic Asset Management Inc. Has $2.61 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Mystic Asset Management Inc. boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 313,347 shares of the company’s stock after acquiring an additional 5,900 shares during the quarter. Mystic Asset Management Inc. owned 0.59% of Zevra Therapeutics worth $2,613,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ZVRA. Raymond James Financial Inc. acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth approximately $224,000. Charles Schwab Investment Management Inc. increased its holdings in Zevra Therapeutics by 23.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,504 shares of the company’s stock valued at $1,247,000 after purchasing an additional 28,148 shares in the last quarter. IFG Advisors LLC raised its position in Zevra Therapeutics by 10.0% in the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock valued at $242,000 after purchasing an additional 2,650 shares during the last quarter. Rhumbline Advisers boosted its stake in Zevra Therapeutics by 18.4% in the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after purchasing an additional 10,573 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Zevra Therapeutics during the fourth quarter worth $94,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Trading Up 0.5 %

Shares of NASDAQ ZVRA opened at $8.35 on Tuesday. Zevra Therapeutics, Inc. has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm has a market capitalization of $451.87 million, a P/E ratio of -4.24 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company’s 50 day simple moving average is $7.92 and its 200 day simple moving average is $8.17.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. On average, analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ZVRA shares. Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Guggenheim increased their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $22.14.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.